PIK3CD and neoplasm: Apitolisib, a novel oral PI3K/mTOR inhibitor developed by Genentech, has shown anti-tumour activity in breast, prostate, endometrial, and other cancers by blocking the cell cycle and thereby inducing apoptosis.113